english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Diclofenac: a habit that needs changing

Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), is routinely used, despite evidence of a greater risk of adverse cardiovascular events when compared with other NSAIDs such as ibuprofen or naproxen, whereas it offers no additional benefit.
1 December 2019

Anti-inflammatory drugs: risks for the kidneys even in young, healthy adults

Taking nonsteroidal anti-inflammatory drugs (NSAIDs) presents risks of nephrotoxicity in young people during intense physical exercise, especially in hot weather.
1 December 2019

Sore throat: paracetamol is the best option

Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to be somewhat more effective than paracetamol, but they expose patients to more serious side effects.
1 December 2019

Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection

FEATURED REVIEW First-line therapy for patients with HIV infection is usually based on triple therapy. When sustained virological suppression has been achieved, treatment "simplification" can sometimes be considered. Is the two-drug regimen dolutegravir + rilpivirine (Juluca°) any better than other treatment options?
Full review (3 pages) available for download by subscribers.
1 November 2019

In the November issue of Prescrire International - Gliptins: joint pain and exposure to NSAIDs

FREE DOWNLOAD In the Adverse Effects section of the November issue, the results of a study by the independent French medical journal Prescrire, based on data from France's national health insurance system.
Full text available for free download.
1 November 2019

Gemtuzumab ozogamicin (Mylotarg°) in acute myeloid leukaemia: no proven benefits

According to currently available clinical evaluation data, gemtuzumab ozogamicin (Mylotarg°) does not provide tangible benefits for patients with acute myeloid leukaemia.
1 November 2019

Fenspiride (Pneumorel°): serious adverse effects reported over two decades

Despite serious adverse effects reported for more than 20 years, fenspiride (Pneumorel°) was only withdrawn from the market in 2019.
1 November 2019

Industrial protectionism and medicines: too many damaging effects

Pharmaceutical companies benefit from strong industrial protection which allows them to charge exorbitant prices for their medicines for a very long time.
1 November 2019

New special section: "Mediator° - the criminal trial"

09 October 2019

  The 2019 "Prescrire Prize" is awarded in Paris to
  3 noteworthy books about health and healthcare

The recipients of the 2019 "Prescrire Prize" book awards were announced on 3 October 2019. The prize is awarded to works of particular interest to the general public and/or healthcare professionals.
03 October 2019

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90